| CAS NO: | 1430844-80-6 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 658.81 |
|---|---|
| Formula | C38H38N6O3S |
| CAS No. | 1430844-80-6 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 100 mg/mL (151.8 mM) |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| Solubility (In vivo) | NA |
| Synonyms | A-1331852; A 1331852; A1331852 |
| In Vitro | In vitro activity: A-1331852 exhibits remarkable potency both as a single agent and in combination with TKIs in killing primary CD34+ CML cell. Also, It has remarkable potency in inducing apoptosis in these cells at low nanomolar concentrations as early as 1 h post-treatment Cell Assay: Immunoprecipitation of BCL-XL is carried out in K562 cells, exposed to A-1331852 (100 nM) for 0-2 h, and the eluted complexes are immunoblotted for the indicated proteins. The input cell lysates and the immunodepleted supernatant (labeled as Flow-through) are immunoblotted to check the efficiency of the immunoprecipitation. |
|---|---|
| In Vivo | Previous animal study found that A-1331852 could demonstrate antitumor efficacy in the Molt-4 xenograft model, such as tumor regressions as a single agent. In addition, in the NCI-H1963.FP5 xenograft model of SCLC, it was found that A-1331852 combined with venetoclax was able to recapitulate the efficacy of navitoclax |
| Animal model | SCID and SCID-bg mice |
| Formulation & Dosage | Formulated in 60% Phosal 50 PG, 27.5 % PEG 400, 10% ethanol, and 2.5% DMSO; 25 mg/kg; Oral gavage |
| References | Sci Transl Med. 2015 Mar 18;7(279):279ra40; Leukemia. 2016 Jun;30(6):1273-81. |
m.cnreagent.com